Show simple item record

dc.contributor.authorKaminski, R.W.
dc.contributor.authorPasetti, M.F.
dc.contributor.authorAguilar, A.O.
dc.date.accessioned2019-12-25T18:07:11Z
dc.date.available2019-12-25T18:07:11Z
dc.date.issued2019
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85076299283&doi=10.1093%2fcid%2fciz909&partnerID=40&md5=870ca2310219837c21932e68f7be16d7
dc.identifier.urihttp://hdl.handle.net/10713/11537
dc.description.abstractModerate to severe diarrhea caused by Shigella is a global health concern due to its substantial contribution to morbidity and mortality in children aged <5 years in low- and middle-income countries. Although antibiotic treatment can be effective, emerging antimicrobial resistance, limited access, and cost affirm the role of vaccines as the most attractive countermeasure. Controlled human infection models (CHIMs) represent a valuable tool for assessing vaccine efficacy and potentially accelerating licensure. Currently, immunological analysis during CHIM studies is customized based on vaccine type, regimen, and administration route. Additionally, differences in type of immunoassays and procedures used limit comparisons across studies. In November 2017, an expert working group reviewed Shigella CHIM studies performed to date and developed consensus guidelines on prioritization of immunoassays, specimens, and collection time points. Immunoassays were ranked into 3 tiers, with antibodies to Shigella lipopolysaccharide (LPS) being the highest priority. To facilitate comparisons across clinical studies, a second workshop was conducted in December 2017, which focused on the pathway toward a recognized enzyme-linked immunosorbent assay (ELISA) to determine serum immunoglobulin G titers against Shigella LPS. The consensus of the meeting was to establish a consortium of international institutions with expertise in Shigella immunology that would work with the National Institute for Biological Standards and Control to establish a harmonized ELISA, produce a reference sera, and identify a reliable source of Shigella LPS for global utilization. Herein we describe efforts toward establishing common procedures to advance Shigella vaccine development, support licensure, and ultimately facilitate vaccine deployment and uptake. Copyright The Author(s) 2019.en_US
dc.description.sponsorshipThis supplement is sponsored by the Bill & Melinda Gates Foundation.en_US
dc.description.urihttps://doi.org/10.1093/cid/ciz909en_US
dc.language.isoen_USen_US
dc.publisherOxford University Pressen_US
dc.relation.ispartofClinical infectious diseases
dc.subjectShigellaen_US
dc.subjecthuman infection modelen_US
dc.subjectimmunoassaysen_US
dc.subjectvaccineen_US
dc.titleConsensus Report on Shigella Controlled Human Infection Model: Immunological Assaysen_US
dc.typeArticleen_US
dc.identifier.doi10.1093/cid/ciz909
dc.identifier.pmid31816067


This item appears in the following Collection(s)

Show simple item record